This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Thank you for your interest in Bayer Oncology. We are committed to supporting healthcare professionals with the resources and information they need.​

If you’re interested in learning more about Xofigo or another product within our Oncology portfolio or would like to arrange a visit from one of our knowledgeable representatives, we’re here to help!​

Xofigo Colleagues

Daniela Felice
Daniela Felice

MSL Oncology

Mobile: +353 87 132 9213

Email:

Dominic Redmond
Dominic Redmond

Product Manager

Mobile: +353 86 6075448

Email:

 
dominic.redmond@bayer.com

Anne Monaghan
Anne Monaghan

Oncology Key Account Manager

Mobile: +353 87 991 3062

Email: anne.monaghan@bayer.com

Please fill out the short form below and our team will get back to you promptly to address your inquiry or set up a convenient time for a visit.​

We look forward to connecting with you soon.​

Please note that we will aim to respond to your request within 5 working days.

Xofigo Logo
About Xofigo®▼ (radium-223 dichloride)
Access key information about Xofigo®.
PP-XOF-IE-0127-1, January 2026
arrow_forward
Xofigo Logo
Xofigo®▼ (radium-223 dichloride) | Efficacy
Explore efficacy of Xofigo®.
PP-XOF-IE-0129-1, February 2026
arrow_forward
Xofigo Logo
Xofigo®▼(radium-223 dichloride) | Safety
Learn more about safety profile of Xofigo®.
PP-XOF-IE-0130-1, February 2026
arrow_forward

PP-XOF-IE-0133-1   |   February 2026

 

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse reactions.